Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Q4 2025 value amounting to $304000.0.

  • Vanda Pharmaceuticals' Depreciation & Amortization (CF) rose 1603.05% to $304000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $1.1 million, marking a year-over-year increase of 2255.56%. This contributed to the annual value of $1.1 million for FY2025, which is 2255.56% up from last year.
  • Per Vanda Pharmaceuticals' latest filing, its Depreciation & Amortization (CF) stood at $304000.0 for Q4 2025, which was up 1603.05% from $301000.0 recorded in Q3 2025.
  • Vanda Pharmaceuticals' 5-year Depreciation & Amortization (CF) high stood at $374000.0 for Q4 2021, and its period low was $200000.0 during Q3 2023.
  • For the 5-year period, Vanda Pharmaceuticals' Depreciation & Amortization (CF) averaged around $277000.0, with its median value being $287500.0 (2022).
  • Per our database at Business Quant, Vanda Pharmaceuticals' Depreciation & Amortization (CF) crashed by 3311.04% in 2023 and then surged by 3935.19% in 2025.
  • Quarter analysis of 5 years shows Vanda Pharmaceuticals' Depreciation & Amortization (CF) stood at $374000.0 in 2021, then dropped by 24.06% to $284000.0 in 2022, then decreased by 27.82% to $205000.0 in 2023, then rose by 27.8% to $262000.0 in 2024, then increased by 16.03% to $304000.0 in 2025.
  • Its last three reported values are $304000.0 in Q4 2025, $301000.0 for Q3 2025, and $267000.0 during Q2 2025.